Severe hypoglycemia caused by a small dose of repaglinide and concurrent use of nilotinib and febuxostat in a patient with type 2 diabetes-Reference-Cited by-同舟云学术

Severe hypoglycemia caused by a small dose of repaglinide and concurrent use of nilotinib and febuxostat in a patient with type 2 diabetes

Published:2020-04-08 Issue:4 Volume:11 Page:388-392
ISSN:2190-1678
Container-title:Diabetology International
language:en
Short-container-title:Diabetol Int

Author:

Komatsu Hitomi,Enomoto Mariko,Shiraishi Hisashi,Morita Yasuyo,Hashimoto Daisuke,Nakayama Shuichi,Funakoshi Shogo,Hirano Seiki,Terada Yoshio,Miyamura Mitsuhiko,Fujimoto Shimpei

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13340-020-00434-w.pdf

Reference29 articles.

1. Bidstrup TB, Bjørnsdottir I, Sidelmann UG, Thomsen MS, Hansen KT. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol. 2003;56:305–14.

2. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia. 2003;46:347–51.

3. Niemi M, Kajosaari LI, Neuvonen M, Backman JT, Neuvonen PJ. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. Br J Clin Pharmacol. 2004;57:441–7.

4. Niemi M, Neuvonen PJ, Kivistö KT. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther. 2001;70:58–655.

5. Wei Y, Lin FJ, Lin SY, Wang CC. Risk of hypoglycemia and concomitant use of repaglinide and clopidogrel: a population-based nested case-control study. Clin Pharmacol Ther. 2019;106:1346–52.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SLCO1B1 c.521T>C gene polymorphism decreases hypoglycemia risk in sulfonylurea-treated type 2 diabetic patients;Drug Metabolism and Personalized Therapy;2022-09-28

2. Correction to: Severe hypoglycemia caused by a small dose of repaglinide and concurrent use of nilotinib and febuxostat in a patient with type 2 diabetes;Diabetology International;2020-04-23